56 results about "Tetracaine" patented technology

It comprises a mixture of lidocaine, prilocaine and tetracaine, or their pharmaceutically acceptable salts. The preferred composition comprises the following components in the indicated approximate w / w percentages: 1.5% of lidocaine base; 1.5% of prilocaine base; 4% of tetracaine base; 10% of methylpynrolidone; 2% of dimethyl sulfoxide; 0.08% of topical hyaluronidase; 1.5% of guar gum; 1% of Tween-20; 0.5% of Tween-80, and the necessary amount of water to 100%. It exhibits a a high concentration on skin, a deep anesthetic effect and a significantly more rapid onset of the anesthetic effect than comparable transdermal anesthetics.

The present invention includes a catheter locking solution having both antimicrobial and anticoagulant properties including a local anesthetic and a viscosifying agent. The local anesthetic of the present invention may be an amino amide; an amino ester; an aminoacylanilide; an aminoalkyl benzoate; an amino carbonate; an N-phenylamidine compound; an N-aminoalkyl amid; an aminoketone, or combinations and mixtures thereof. In a particular embodiment of the present invention, the local anesthetic is tetracaine or dibucaine.

A dermal drug delivery system is provided which comprises at least two components, for example, a sheet of a solid and flexible material, and a vehicle liquid comprising a solvent and optionally other ingredients. A drug, which can be unstable in said solvent but needs the solvent for being delivered into the skin, can be impregnated in the sheet. Other ingredients, such as agents for fastening the drug on the sheet can also be impregnated in the sheet. These two components may be stored separately and joined either shortly before or at the time of application. To use the system, the vehicle liquid may be applied either on the target skin area or on the sheet, and the sheet may then be applied on the target skin area so that the vehicle liquid is positioned between the sheet and the skin and brought into contact with the ingredients impregnated in the sheet. After the sheet and the vehicle liquid are combined in this way, the ingredients in the sheet and in the vehicle liquid are joined to form a combined formulation that is capable of delivering a drug through the skin at a desired rate. The sheet may have low enough permeability to the solvent or its vapor to control the time it takes for the solvent to evaporate across the sheet. When an appropriate local anesthetic agent, such as a tetracaine, is the drug, some embodiments of the system can have wide applications in anesthesia and pain control.

The invention discloses a pharmaceutical composition, a patch, and preparation methods and application of the pharmaceutical composition and the patch. The pharmaceutical composition comprises a simplex anesthetic active ingredient, wherein the anesthetic active ingredient is composed of anesthetic active components dissolved in water and anesthetic active components in undissolved state; mass percentage of the anesthetic active ingredient in the pharmaceutical composition is higher than 2%; mass percentage of the anesthetic active components dissolved in water in the pharmaceutical composition is lower than 1%; and the anesthetic active ingredient is selected from lidocaine, tetracaine, bupivacaine, atecaine, cincocaine, dibucaine, eticaine, levobupivacaine, mepivacaine, propivacaine, ropivacaine, trimethylcaine, benzocaine or procaine. The pharmaceutical composition and the patch are capable of achieving continuous analgesic effects for 12-30 hours; moreover, the patch is capable ofresisting certain external pressing force so as to protect the covered formula layers from being squeezed out, thereby maintaining thickness of the formula layers.

The present invention provides a medical device, which comprises: a microneedle array, and a coating disposed on the microneedles, wherein the coating comprises: a local anesthetic selected from lidocaine, Prilocaine and combinations thereof; and local anesthetic dose sustained-release components selected from tetracaine, ropivacaine, bupivacaine, procaine and combinations thereof; wherein based on the solids in the coating The total weight of the local anesthetic is present in an amount of at least 1% by weight, and wherein the weight ratio of the local anesthetic and the dose-extending component is a non-eutectic weight ratio; a medical device comprising An array of dissolving microneedles comprising: a dissolvable matrix material; at least 1% by weight of a local anesthetic selected from the group consisting of lidocaine, prilocaine, and combinations thereof; and a local anesthetic dose sustained release component , which is selected from tetracaine, ropivacaine, bupivacaine, procaine, and combinations thereof; wherein the weight ratio of the local anesthetic and the dose-sustaining component is a non-eutectic weight ratio, and wherein the weight % based on the total weight of solids in all portions of the dissolvable microneedles containing the local anesthetic; a method of using the device to provide sustained release of a locally delivered dose of local anesthetic in mammalian tissue; and a method of manufacturing method of the device.

The invention discloses a method for preparing tetracaine, which comprises the following steps in sequence: (1) preparing N-butyl p-aminobenzoic acid through catalytic reduction reaction of p-aminobenzoic acid and n-butyraldehyde; (2) in step (1) (3) N-butyl p-aminobenzoic acid treated with sodium hydroxide is directly reacted with N,N-dimethylchloroethylamine hydrochloride without purification and separation Tetracaine. The method of the invention has few steps, simple operation, easier cleaning and higher product yield.